Drugs / JNJ-73763989
Trials 13
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2021-11-08 | ST Pharm Co., Ltd. | Results JNJ-3989, 임상3상 준비, B형간염바이러스 세계를 뒤흔들 것 stpharm.co.kr ↗
JNJ-3989를 4주 간격으로 3회 400mg씩 투여한 결과 39%의 환자에서 투약 종료 후 48주 및 최대 392일 차 만성 B형간염 바이러스가 1log10IU/mL 이상 감소(기능적 완치 가능성 확인) |
| 2020-08-28 | Arrowhead Pharmaceuticals | Results Arrowhead and Collaborator Janssen Present Phase 2 Clinical Data on Investigational Hepatitis B Therapeutic JNJ-3989 at The Digital Liver Congress arrowheadpharma.com ↗
For the first time in patients with CHB, siRNA therapy resulted in sustained, off-treatment ≥1log10 IU/mL reductions in HBsAg through to 48 weeks in 39% of patients after the last JNJ-3989 dose |
| 2019-11-08 | Arrowhead Pharmaceuticals | Results Arrowhead and Collaborator Janssen Present Phase 2 Clinical Data for Investigational Hepatitis B Regimens at The Liver Meeting® 2019 arrowheadpharma.com ↗
The data is being presented in two poster presentations at The Liver Meeting®, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD). |
All press releases naming this drug 6 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-10-31 | GlaxoSmithKline | GSK enters agreement to obtain exclusive license for JNJ-3989 to expand the development of bepirovirsen gsk.com ↗ |
| 2023-10-31 | Arrowhead Pharmaceuticals | GSK enters agreement to obtain exclusive license for JNJ-3989 to expand the development of bepirovirsen arrowheadpharma.com ↗ |
| 2021-11-08 | ST Pharm Co., Ltd. | JNJ-3989, 임상3상 준비, B형간염바이러스 세계를 뒤흔들 것 stpharm.co.kr ↗ |
| 2020-08-28 | Arrowhead Pharmaceuticals | Arrowhead and Collaborator Janssen Present Phase 2 Clinical Data on Investigational Hepatitis B Therapeutic JNJ-3989 at The Digital Liver Congress arrowheadpharma.com ↗ |
| 2019-11-08 | Arrowhead Pharmaceuticals | Arrowhead and Collaborator Janssen Present Phase 2 Clinical Data for Investigational Hepatitis B Regimens at The Liver Meeting® 2019 arrowheadpharma.com ↗ |
| 2019-04-12 | Arrowhead Pharmaceuticals | Arrowhead Presents Clinical Data on JNJ-3989 (ARO-HBV) at The International Liver Congress™ arrowheadpharma.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-73763989 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04963738 ↗ |
| Known as | JNJ-3989 | “BACKGROUND & AIMS: JNJ-73763989 (JNJ-3989) is a small-interfering RNA composed of two triggers targeting the HBsAg and HBx protein open reading frame, designed to target all...” PMID 41362713 ↗ Oct 20253“JNJ-73763989 (JNJ-3989) is a small interfering ribonucleic acid (siRNA) targeting all hepatitis B virus (HBV) messenger ribonucleic acid (mRNAs).” NCT05275023 ↗ “following a subcutaneous (SC) injection of JNJ-73763989 (JNJ-3989) in participants with liver cirrhosis” NCT04208386 ↗ “the small-interfering RNA JNJ-73763989 (JNJ-3989)” PMID 38583491 ↗ Apr 2024 |
| Action | Inhibit | “designed to target all HBV RNAs for degradation” PMID 41362713 ↗ Oct 2025 |
| Modality | Small interfering RNA (siRNA) | “JNJ-73763989 (JNJ-3989) is a small-interfering RNA composed of two triggers targeting the HBsAg and HBx protein open reading frame” PMID 41362713 ↗ Oct 2025 |
| Route | Subcutaneous | “JNJ-73763989 is a liver-targeted antiviral therapeutic for subcutaneous injection” NCT03982186 ↗ |